Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ex-vivo expanded γδ T cell infusion (Chinese PLA General Hospital)
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an adoptive cell therapy involving the ex-vivo expansion and subsequent infusion of donor-derived gamma-delta (γδ) T cells. Developed by the Chinese PLA General Hospital, this therapy is specifically investigated for patients with hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and lymphoma, who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). γδ T cells are unique T cell subsets that bridge innate and adaptive immunity, recognizing tumor cells in an MHC-independent manner. This recognition is primarily mediated through the γδ T-cell receptor (TCR) and the NKG2D receptor, which bind to stress-induced ligands such as MICA/B and phosphoantigens on malignant cells. By utilizing donor-derived cells post-transplant, the therapy aims to enhance the graft-versus-leukemia (GVL) effect to prevent or treat relapse while minimizing the risk of graft-versus-host disease (GVHD).
- Other names
- Donor-derived γδ T cell infusionGamma-delta T cell therapyEx-vivo expanded γδ T cell infusion
02
Targets
MICB (Major histocompatibility complex class i-related protein B)NKG2D (Natural killer group 2 member D receptor)BTN3A1 (Butyrophilin 3A1/2A1 complex)ULBP (ULBP family)Vγ9Vδ2 TCR (γδ T cell receptor–butyrophilin 2A1/butyrophilin 3A1–phosphoantigen complex)
Beyond the preview
Go deeper on Ex-vivo expanded γδ T cell infusion (Chinese PLA General Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ex-vivo expanded γδ T cell infusion (Chinese PLA General Hospital).